{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:44:42Z","timestamp":1790819082097,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) is developed in the era of second-generation antipsychotics and is suitable for evaluation of the low incidence of extrapyramidal symptoms occurring in the treatment of atypical antipsychotics, as well as the relationship between personal and social functioning. The study was carried out at the Institute of Mental Health in Serbia in 2015 Study used the 127 DIEPSS video clips material, recorded from 1987 till 2015. Four raters performed the assessment simultaneously, individually rating one assigned item immediately after seeing the video clip. For the purpose of evaluating test-retest reliability the second assessment of the same material was performed nine months after the first assessment. Inter-rater reliability was high for each individual item, with ICCs ranging from 0.769 to 0.949. The inter-rater reliability was highest for akathisia item and lowest for dyskinesia. The test-retest reliability was high for each individual item, with ICC ranging from 0.713 to 0.935. The test-retest reliability was highest for bradykinesia item and lowest for dystonia. The Serbian version of DIEPSS has high level of inter-rater and test-retest reliability. High values of concordance rates (ICC\u2009&gt;\u20090.7) for each evaluated individual item suggest that items of DIEPSS are well defined.<\/jats:p>","DOI":"10.1038\/s41598-017-08706-3","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T15:26:18Z","timestamp":1502205978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) Serbian Language version: Inter-rater and Test-retest Reliability"],"prefix":"10.1038","volume":"7","author":[{"given":"Ami","family":"Peljto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljubica","family":"Zamurovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica Pejovic","family":"Milovancevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8982-4580","authenticated-orcid":false,"given":"Branko","family":"Aleksic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusica Lecic","family":"Tosevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"key":"8706_CR1","doi-asserted-by":"crossref","unstructured":"Schatzberg, A. F. & Nemeroff, C. B. The American Psychiatric Publishing Textbook of Psychopharmacology (2009).","DOI":"10.1176\/appi.books.9781585623860"},{"key":"8706_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11126-014-9290-x","volume":"85","author":"AAD Ara\u00fajo","year":"2014","unstructured":"Ara\u00fajo, A. A. D. et al. Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs. Psychiatric Quarterly \n                           85, 357\u2013367 (2014).","journal-title":"Psychiatric Quarterly"},{"key":"8706_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","volume":"7","author":"A \u00dc\u00e7ok","year":"2008","unstructured":"\u00dc\u00e7ok, A. & Gaebel, W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry \n                           7, 58\u201362 (2008).","journal-title":"World Psychiatry"},{"key":"8706_CR4","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. (5th ed. Arlington, V.A.) Ch 19, 407\u2013414 (American Psychiatric Publishing, 2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"8706_CR5","unstructured":"World Health Organization. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines (Geneva: World Health Organization, 1992)."},{"key":"8706_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ncl.2010.10.002","volume":"29","author":"SN Caroff","year":"2011","unstructured":"Caroff, S. N., Hurford, I., Lybrand, J. & Campbell, E. C. Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial. Neurologic Clinics \n                           29, 127\u2013148 (2011).","journal-title":"Neurologic Clinics"},{"key":"8706_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2045125313510195","volume":"4","author":"PM Haddad","year":"2013","unstructured":"Haddad, P. M. et al. SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. Therapeutic Advances in Psychopharmacology \n                           4, 15\u201321 (2013).","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"8706_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"45","author":"GM Simpson","year":"1970","unstructured":"Simpson, G. M. et al. A Rating Scale For Extrapyramidal Side Effects. Acta Psychiatrica Scandinavica \n                           45, 11\u201319 (1970).","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"8706_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes, T. R. A rating scale for drug-induced akathisia. The British Journal of Psychiatry \n                           154, 672\u2013676 (1989).","journal-title":"The British Journal of Psychiatry"},{"key":"8706_CR10","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1176\/ps.39.11.1172","volume":"39","author":"MR Munetz","year":"1988","unstructured":"Munetz, M. R. & Benjamin, S. How to Examine Patients Using the Abnormal Involuntary Movement Scale. Psychiatric Services \n                           39, 1172\u20131177 (1988).","journal-title":"Psychiatric Services"},{"key":"8706_CR11","first-page":"233","volume":"7","author":"G Chouinard","year":"1980","unstructured":"Chouinard, G., Ross-Chouinard, A., Annable, L. & Jones, B. D. The extrapyramidal symptom rating scale. Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques \n                           7, 233\u2013236 (1980).","journal-title":"Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"},{"key":"8706_CR12","unstructured":"Inada, T. Evaluation and Diagnosis of Drug-induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage. Tokyo: Seiwa Shoten Publishers; 1996."},{"key":"8706_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0920-9964(01)00314-0","volume":"57","author":"T Inada","year":"2002","unstructured":"Inada, T., Yagi, G. & Miura, S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophrenia Research \n                           57, 227\u2013238 (2002).","journal-title":"Schizophrenia Research"},{"key":"8706_CR14","unstructured":"Inada, T. A Second-generation Rating Scale for Antipsychotic-induced Extrapyramidal Symptoms: Drug-induced Extrapyramidal Symptoms Scale. Seiwa Shoten Publishers Inc, Tokyo 2009. p. 17."},{"key":"8706_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.psychres.2016.01.069","volume":"238","author":"IJ Park","year":"2016","unstructured":"Park, I. J. et al. The longitudinal trends in the relationship between drug-induced extrapyramidal symptoms and personal and social performance in a population of the patients with schizophrenia: A latent growth model. Psychiatry Research \n                           238, 33\u201339 (2016).","journal-title":"Psychiatry Research"},{"key":"8706_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/comp.2002.35908","volume":"43","author":"J-H Kim","year":"2002","unstructured":"Kim, J.-H. et al. Subjective emotional experience and cognitive impairment in drug-induced akathisia. Comprehensive Psychiatry \n                           43, 456\u2013462 (2002).","journal-title":"Comprehensive Psychiatry"},{"key":"8706_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/JCP.0b013e3181c914b3","volume":"30","author":"W Knol","year":"2010","unstructured":"Knol, W., Keijsers, C. J., Jansen, P. A. & Marum, R. J. V. Systematic Evaluation of Rating Scales for Drug-Induced Parkinsonism and Recommendations for Future Research. Journal of Clinical Psychopharmacology \n                           30, 57\u201363 (2010).","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"8706_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1177\/0269881115593893","volume":"29","author":"AMV Strien","year":"2015","unstructured":"Strien, A. M. V., Keijsers, C. J., Derijks, H. J. & Marum, R. J. V. Rating scales to measure side effects of antipsychotic medication: A systematic review. Journal of Psychopharmacology \n                           29, 857\u2013866 (2015).","journal-title":"Journal of Psychopharmacology"},{"key":"8706_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1248\/yakushi.16-00219","volume":"137","author":"E Kose","year":"2017","unstructured":"Kose, E., Uno, K. & Hayashi, H. Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database. Yakugaku Zasshi \n                           137, 111\u2013120 (2017).","journal-title":"Yakugaku Zasshi"},{"key":"8706_CR20","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1002\/sim.935","volume":"20","author":"B Giraudeau","year":"2001","unstructured":"Giraudeau, B. & Mary, J. Y. Planning a reproducibility study: how many subjects and how many replicates per subject for an expected width of the 95 per cent confidence interval of the intraclass correlation coefficient. Statistics in Medicine \n                           20, 3205\u20133214 (2001).","journal-title":"Statistics in Medicine"},{"key":"8706_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/00005053-197611000-00003","volume":"163","author":"JJ Bartko","year":"1976","unstructured":"Bartko, J. J. & Carpenter, W. T. On The Methods And Theory Of Reliability. The Journal of Nervous and Mental Disease \n                           163, 307\u2013317 (1976).","journal-title":"The Journal of Nervous and Mental Disease"},{"key":"8706_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/sj.mp.4002136","volume":"14","author":"S Leucht","year":"2008","unstructured":"Leucht, S., Arbter, D., Engel, R. R., Kissling, W. & Davis, J. M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry \n                           14, 429\u2013447 (2008).","journal-title":"Molecular Psychiatry"},{"key":"8706_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/schbul\/sbq042","volume":"38","author":"C Rummel-Kluge","year":"2012","unstructured":"Rummel-Kluge, C. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophrenia Buletin. \n                           38, 167\u2013177 (2012).","journal-title":"Schizophrenia Buletin."},{"key":"8706_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2165\/00002018-200831070-00005","volume":"31","author":"S Ormerod","year":"2008","unstructured":"Ormerod, S., McDowell, S. E., Coleman, J. J. & Ferner, R. E. Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis. Drug Safety \n                           31, 597\u2013607 (2008).","journal-title":"Drug Safety"},{"key":"8706_CR25","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/mds.10255","volume":"17","author":"J-H Kim","year":"2002","unstructured":"Kim, J.-H. et al. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): A practical combined rating scale for drug-induced movement disorders. Movement Disorders \n                           17, 1354\u20131359 (2002).","journal-title":"Movement Disorders"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-08706-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-08706-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-08706-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T08:40:40Z","timestamp":1671784840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-08706-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["8706"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-08706-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,14]]},"assertion":[{"value":"8 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Inada has received one or more of honoraria for lectures, speakers, consultants, and\/or royalties, for 5 years recently from Otsuka, Dainippon Sumitomo, Astellas, Tanabe Mitsubishi, Takeda, Pfizer, Eli Lilly, Janssen, Meiji-Seika, Yoshitomi Yakuhin, Kyowa Yakuhin, MSD and Glaxo Smith Kline pharmaceutical companies, Mochida. All other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8105"}}